| Welcome
and Introduction |
|
|
Dominique
Duchêne, EUFEPS President, Paris FR
Ole J. Bjerrum, Conference Chair, Copenhagen DK |
| |
Setting
the stage |
|
Moderators
|
Biotech
medicines: Present and future aspects
Trevor M. Jones, London UK |
|
Session
I
|
Generation
and down stream processing of therapeutic
proteins |
|
Moderators:
|
Manuel
Carrondo, Oeiras PT
Wolfram Carius, Biberach DE |
|
•
|
Value
through optimisation of bioprocesses
Rolf Werner, Biberach DE |
|
•
|
Current
trends in cell line and cell culture development
Alain Bernard, Corsier-sur-Vevey CH |
|
•
|
Downstream
processing: Implications of new technologies on process design
illustrated with examples from insulin and rFVIIa Inger
Mollerup, Bagsvaerd DK |
|
•
|
Development
and regulation of gene transfer medicinal products
Klaus Cichutek, Langen DE |
|
Session
II
|
Delivery
and formulation aspects |
|
Moderators:
|
Leo
de Leede, Leiden NL
Claus-Michael Lehr, Saarbrücken DE |
|
•
|
Protein
formulations: Bottlenecks and challenges
Daan Crommelin, Utrecht NL |
|
•
|
Overcoming
cellular barriers with large molecules
Claus-Michael Lehr, Saarbrücken DE |
|
•
|
Hydrophilic
systems for protein delivery
Leo de Leede, Leiden NL |
|
•
|
New
hydrophobic polymers for protein delivery
Achim Göpferich, Regensburg DE |
|
•
|
Systemic
aerosol therapy with biopharmaceuticals
Martin Kohlhäufl, Gauting DE |
| Monday
Evening Break-out Sessions |
|
•
|
Downstream
industrial processing aspects |
|
•
|
Delivery
and formulation aspects |
|
•
|
Analytical
aspects |
|
|
|
Session
III
|
Rational
exploratory and human development |
|
Moderators:
|
Tudor
Arvinte, Basel CH
Karsten Skydsgaard, Bagsvaerd DK |
|
•
|
Analytical
techniques to establish therapeutic activity
Tudor Arvinte, Basel CH |
|
•
|
Trial simulation
modelling in drug development
Lars Erichsen, Bagsvaerd DK
|
|
•
|
Comparability
and bioequivalence issues regarding pharmaceutical biologicals
James Bausch, Union NJ USA |
|
•
|
Immunogenicity
of biotech products
Kathryn Stein, Rockville MD USA |
|
•
|
Assessment for
immunogenicity.
Steve Swanson, Thousand Oaks CA USA
|
|
Session
IV
|
Generation
and design of antibodies as therapeutics |
| Moderators: |
Ole
J. Bjerrum, Copenhagen DK
Daan Crommelin, Utrecht NL |
|
•
|
A
display-technology based platform for making and engineering
human therapeutic antibodies
Hennie Hoogenboom, Liege BE |
|
•
|
Production
and processing of antibodies
Christina Glad, Lund SE |
|
•
|
Human
antibodies as next generation therapeutics
Jan van de Winkel, Utrecht NL |
|
•
|
Monoclonal
human anti-CD4 antibody. A case study from pre clinic to late
stage development
Claus Moeller, Copenhagen DK |
|
•
|
Remicade,
the full story
Peter C. Taylor, London UK |
| Tuesday
Evening Break-out Sessions |
|
•
|
Antibodies |
|
•
|
Human
clinical development |
|
•
|
Regulatory
aspects: Testing for immunogenicity |
